Navigation Links
Gene promotes 1 in 100 of tumors
Date:12/8/2013

Researchers have identified a gene that drives the development of tumours in over one per cent of all cancer patients. This is the first time that the gene CUX1 has been broadly linked to cancer development.

The team discovered that, when CUX1 is deactivated, a biological pathway is activated that increases tumour growth. Drugs that inhibit the biological pathway are currently being used in the clinic and are in development thus highlighting a potential new targeted therapy for patients with this type of cancer-causing mutation.

Around 300,000 people in the UK each year are diagnosed with cancer, and for more than 3,000 of these patients, an inactive CUX1 gene may be an underlying factor for their disease.

"Our research is a prime example of how understanding the genetic code of cancers can drive the search for targeted cancer therapies that work more effectively and efficiently, says Dr David Adams, lead author from the Wellcome Trust Sanger Institute. "This could improve the lives of thousands of people suffering from cancer."

The team used genetic data from over 7,600 cancer patients, collected and sequenced by the International Cancer Genome Constortium (ICGC) and other groups. They found that in around one per cent of the cancer genomes studied, mutations deactivated CUX1, an event associated with tumour growth.

CUX1 is mutated at a relatively low frequency, but across many different types of cancer. Because previous studies focused on genes that are mutated at a high rate in one cancer type to find cancer drivers, CUX1 was missed as a driver of cancer.

"Our work harnesses the power of combining large-scale cancer genomics with experimental genetics," says Dr Chi Wong, first author from the Wellcome Trust Sanger Institute and practising Haematologist at Addenbrooke's Hospital. "CUX1 defects are particularly common in myeloid blood cancers, either through mutation or acquired loss of chromosome 7q. As these patients have a dismal prognosis currently, novel targeted therapies are urgently needed."

"Data collected from large consortia such the ICGC, provides us with a new and broader way to identify genes that can underlie the development of cancers," says Professor David Tuveson from Cold Spring Harbor Laboratory. "We can now look at cancers as groups of diseases according to their tissues of origin and collectively examine and compare their genomes."

The team silenced CUX1 in cultured cells to understand how inactivating it might lead to the development of tumours. They found that when CUX1 is deactivated, it had a knock-on effect on a biological inhibitor, PIK3IP1, reducing its inhibitory effects. This mobilises an enzyme responsible for cell growth, phosphoinositide 3-kinase (PI3K), increasing the rate of tumour progression.

The team has already identified several dozen other genes that when mutated at a low frequency could promote cancer development. They plan to silence these genes in mice to fully understand how their inactivation may lead to cancer development and the mechanisms by which this occurs.

"Drugs that inhibit PI3K signalling are currently undergoing clinical trial," says Professor Paul Workman, Deputy Chief Executive and Head of Cancer Therapeutics at The Institute of Cancer Research, London. "This discovery will help us to target these drugs to a new group of patients who will benefit from them and could have a dramatic effect on the lives of many cancer sufferers."


'/>"/>

Contact: Aileen Sheehy
press.office@sanger.ac.uk
44-012-234-92368
Wellcome Trust Sanger Institute
Source:Eurekalert

Related biology news :

1. Single protein promotes resistance to widely used anti-estrogen drugs
2. An economical, effective and biocompatible gene therapy strategy promotes cardiac repair
3. New Genetics educational resource promotes active learning
4. Breast milk promotes a different gut flora growth than infant formulas
5. NJIT professor promotes building material of millennium: Autoclave aerated concrete
6. Team finds gene that promotes drug resistance in cancer
7. Environmental complexity promotes biodiversity
8. Testosterone promotes reciprocity in the absence of competition
9. Dysfunctional chemokine receptor promotes candidiasis
10. Treadmill step training promotes motor function after incomplete spinal cord injury
11. Nanotherapy: Treating deadly brain tumors by delivering big radiation with tiny tools
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2018)... ... November 14, 2018 , ... Researchers at the ... up the analysis and publication of biomedical data from many months or years ... now, the primary method available to share biomedical research data has been through ...
(Date:11/14/2018)... ... 2018 , ... In recognition of World Diabetes Day, Diopsys is lending its ... company is reaching out to help educate patients and the healthcare community about the ... testing for people with the disease. , The American Diabetes Association (ADA) released ...
(Date:11/13/2018)... ... November 13, 2018 , ... Fluence ... controlled-environment cultivation applications. VYPR 2 is well suited for sole-source and supplemental lighting ... growing markets. , “As an all-purpose light which can be adapted to ...
Breaking Biology News(10 mins):
(Date:10/31/2018)... Calif. (PRWEB) , ... October 30, 2018 , ... Pippa Rose is a young Labrador ... around one year old, Pippa suffered a partial tear to the cruciate ligament in her ... to run or go on walks. Kinsley reported that it broke her heart to ...
(Date:10/29/2018)... ... October 29, 2018 , ... PracticeMatch , a company that provides the ... physician career fairs planned for 2019. The company has expanded its offering of virtual ... the areas of the country which have the highest concentrations of resident and fellow ...
(Date:10/24/2018)... , ... October 22, 2018 , ... ... Philip Bourne, PhD, Director of the Data Science Institute, Stephenson Chair of Data ... Scientific Advisory Board. Joining the board of leading scientists and doctors from around ...
(Date:10/18/2018)... ... October 18, 2018 , ... R3 Stem Cell is ... day regenerative therapy training workshop. The discount is good through November 7th, 2018, with ... stem cell and PRP training workshop includes an amazing useful array of hands on ...
Breaking Biology Technology: